U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C17H20F6N2O3
Molecular Weight 414.3427
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FLECAINIDE

SMILES

FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1

InChI

InChIKey=DJBNUMBKLMJRSA-UHFFFAOYSA-N
InChI=1S/C17H20F6N2O3/c18-16(19,20)9-27-12-4-5-14(28-10-17(21,22)23)13(7-12)15(26)25-8-11-3-1-2-6-24-11/h4-5,7,11,24H,1-3,6,8-10H2,(H,25,26)

HIDE SMILES / InChI
Molecular Formula C17H20F6N2O3
Molecular Weight 414.3427
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/pro/flecainide.html

Flecainide is a potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial arrhythmias and tachycardias. Flecainide has local anesthetic activity and belongs to the membrane stabilizing (Class 1) group of antiarrhythmic agents; it has electrophysiologic effects characteristic of the IC class of antiarrhythmics. Flecainide acts on sodium channels on the neuronal cell membrane, limiting the spread of seizure activity and reducing seizure propagation. The antiarrhythmic actions are mediated through effects on sodium channels in Purkinje fibers. Flecainide is a sodium channel blocker, binding to voltage gated sodium channels. It stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses. Ventricular excitability is depressed and the stimulation threshold of the ventricle is increased during diastole. Flecainide is sold under the trade name Tambocor (manufactured by 3M pharmaceuticals). Flecainide went off-patent on February 10, 2004. In addition to being marketed as Tambocor, it is also available in generic version and under the trade names Almarytm, Apocard, Ecrinal, and Flécaine.

Originator

Approval Year

1985
117
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
 67.2 µM [IC50]
Inhibitor
8297
 18.0 µM [Ki]
Inhibitor
8297
 1.49 µM [IC50]
Inhibitor
8297
 7.8 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
Approved
8429
Flecainide

Approved Use

In patients without structural heart disease, Flecainide is indicated for the prevention of - paroxysmal supraventricular tachycardias (PSVT), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms - paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms Flecainide is also indicated for the prevention of - documented ventricular arrhythmias, such as sustained ventricular tachycardia (sustained VT), that in the judgment of the physician, are lifethreatening.

Launch Date

2001
Preventing
Approved
8429
Flecainide

Approved Use

In patients without structural heart disease, Flecainide is indicated for the prevention of - paroxysmal supraventricular tachycardias (PSVT), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms - paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms Flecainide is also indicated for the prevention of - documented ventricular arrhythmias, such as sustained ventricular tachycardia (sustained VT), that in the judgment of the physician, are lifethreatening.

Launch Date

2001
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
355 ng/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/3094570
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FLECAINIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1710 ng/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/3094570
2 mg/kg single, intravenous
dose: 2 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
FLECAINIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
5979 ng × h/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/3094570
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FLECAINIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
6238 ng × h/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/3094570
2 mg/kg single, intravenous
dose: 2 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
FLECAINIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
5.9 μg × h/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/1782978
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FLECAINIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
11.5 h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/1782978
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FLECAINIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
60%
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/6364769
FLECAINIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
1200 mg single, oral
Overdose
Dose: 1200 mg
Route: oral
Route: single
Dose: 1200 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/20562156
Page: p.487
healthy, 18
n = 1
Health Status: healthy
Age Group: 18
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/20562156
Page: p.487
Disc. AE: Unconsciousness, Cyanosis...
AEs leading to
discontinuation/dose reduction:
Unconsciousness
Cyanosis
Bradycardia
Arrhythmia
Sources:
https://pubmed.ncbi.nlm.nih.gov/20562156
Page: p.487
3800 mg single, oral
Overdose
Dose: 3800 mg
Route: oral
Route: single
Dose: 3800 mg
Co-administed with::
diazepam, p.o(50 mg)
loperamide, p.o(20 mg)
Sources:
https://pubmed.ncbi.nlm.nih.gov/3107447
healthy, 28
n = 1
Health Status: healthy
Age Group: 28
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/3107447
Disc. AE: Polymorphic ventricular tachycardia...
AEs leading to
discontinuation/dose reduction:
Polymorphic ventricular tachycardia
Sources:
https://pubmed.ncbi.nlm.nih.gov/3107447
10 g single, oral
Overdose
Dose: 10 g
Route: oral
Route: single
Dose: 10 g
Sources:
https://pubmed.ncbi.nlm.nih.gov/9825278
Page: p.423
healthy, 36
n = 1
Health Status: healthy
Age Group: 36
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/9825278
Page: p.423
Disc. AE: Ventricular tachycardia, Hypotension...
AEs leading to
discontinuation/dose reduction:
Ventricular tachycardia
Hypotension
Cardiopulmonary arrest
Sources:
https://pubmed.ncbi.nlm.nih.gov/9825278
Page: p.423
1 g single, oral
Overdose
Dose: 1 g
Route: oral
Route: single
Dose: 1 g
Co-administed with::
lamotrigine, p.o
quetiapine, p.o
Sources:
https://pubmed.ncbi.nlm.nih.gov/27884575
Page: p.1
unhealthy, 62
n = 1
Health Status: unhealthy
Condition: Atrial fibrillation
Age Group: 62
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/27884575
Page: p.1
Disc. AE: Brugada syndrome, Mental status changes...
AEs leading to
discontinuation/dose reduction:
Brugada syndrome
Mental status changes
Fatigue
Sources:
https://pubmed.ncbi.nlm.nih.gov/27884575
Page: p.1
200 mg 2 times / day multiple, oral
Recommended
Dose: 200 mg, 2 times / day
Route: oral
Route: multiple
Dose: 200 mg, 2 times / day
Sources:
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fa68b35e-9f50-408b-9e70-e84cecf3fd6e&type=display
unhealthy
Health Status: unhealthy
Condition: Paroxysmal supraventricular tachycardias|paroxysmal atrial fibrillation/flutter|Sustained ventricular tachycardia
Sources:
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fa68b35e-9f50-408b-9e70-e84cecf3fd6e&type=display
Disc. AE: Ventricular tachycardia, Cardiac arrest...
AEs leading to
discontinuation/dose reduction:
Ventricular tachycardia
Cardiac arrest
Sources:
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fa68b35e-9f50-408b-9e70-e84cecf3fd6e&type=display
AEs

AEs

AESignificanceDosePopulation
Arrhythmia Disc. AE
1200 mg single, oral
Overdose
Dose: 1200 mg
Route: oral
Route: single
Dose: 1200 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/20562156
Page: p.487
healthy, 18
n = 1
Health Status: healthy
Age Group: 18
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/20562156
Page: p.487
Bradycardia Disc. AE
1200 mg single, oral
Overdose
Dose: 1200 mg
Route: oral
Route: single
Dose: 1200 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/20562156
Page: p.487
healthy, 18
n = 1
Health Status: healthy
Age Group: 18
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/20562156
Page: p.487
Cyanosis Disc. AE
1200 mg single, oral
Overdose
Dose: 1200 mg
Route: oral
Route: single
Dose: 1200 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/20562156
Page: p.487
healthy, 18
n = 1
Health Status: healthy
Age Group: 18
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/20562156
Page: p.487
Unconsciousness Disc. AE
1200 mg single, oral
Overdose
Dose: 1200 mg
Route: oral
Route: single
Dose: 1200 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/20562156
Page: p.487
healthy, 18
n = 1
Health Status: healthy
Age Group: 18
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/20562156
Page: p.487
Polymorphic ventricular tachycardia Disc. AE
3800 mg single, oral
Overdose
Dose: 3800 mg
Route: oral
Route: single
Dose: 3800 mg
Co-administed with::
diazepam, p.o(50 mg)
loperamide, p.o(20 mg)
Sources:
https://pubmed.ncbi.nlm.nih.gov/3107447
healthy, 28
n = 1
Health Status: healthy
Age Group: 28
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/3107447
Cardiopulmonary arrest Disc. AE
10 g single, oral
Overdose
Dose: 10 g
Route: oral
Route: single
Dose: 10 g
Sources:
https://pubmed.ncbi.nlm.nih.gov/9825278
Page: p.423
healthy, 36
n = 1
Health Status: healthy
Age Group: 36
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/9825278
Page: p.423
Hypotension Disc. AE
10 g single, oral
Overdose
Dose: 10 g
Route: oral
Route: single
Dose: 10 g
Sources:
https://pubmed.ncbi.nlm.nih.gov/9825278
Page: p.423
healthy, 36
n = 1
Health Status: healthy
Age Group: 36
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/9825278
Page: p.423
Ventricular tachycardia Disc. AE
10 g single, oral
Overdose
Dose: 10 g
Route: oral
Route: single
Dose: 10 g
Sources:
https://pubmed.ncbi.nlm.nih.gov/9825278
Page: p.423
healthy, 36
n = 1
Health Status: healthy
Age Group: 36
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/9825278
Page: p.423
Brugada syndrome Disc. AE
1 g single, oral
Overdose
Dose: 1 g
Route: oral
Route: single
Dose: 1 g
Co-administed with::
lamotrigine, p.o
quetiapine, p.o
Sources:
https://pubmed.ncbi.nlm.nih.gov/27884575
Page: p.1
unhealthy, 62
n = 1
Health Status: unhealthy
Condition: Atrial fibrillation
Age Group: 62
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/27884575
Page: p.1
Fatigue Disc. AE
1 g single, oral
Overdose
Dose: 1 g
Route: oral
Route: single
Dose: 1 g
Co-administed with::
lamotrigine, p.o
quetiapine, p.o
Sources:
https://pubmed.ncbi.nlm.nih.gov/27884575
Page: p.1
unhealthy, 62
n = 1
Health Status: unhealthy
Condition: Atrial fibrillation
Age Group: 62
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/27884575
Page: p.1
Mental status changes Disc. AE
1 g single, oral
Overdose
Dose: 1 g
Route: oral
Route: single
Dose: 1 g
Co-administed with::
lamotrigine, p.o
quetiapine, p.o
Sources:
https://pubmed.ncbi.nlm.nih.gov/27884575
Page: p.1
unhealthy, 62
n = 1
Health Status: unhealthy
Condition: Atrial fibrillation
Age Group: 62
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/27884575
Page: p.1
Cardiac arrest Disc. AE
200 mg 2 times / day multiple, oral
Recommended
Dose: 200 mg, 2 times / day
Route: oral
Route: multiple
Dose: 200 mg, 2 times / day
Sources:
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fa68b35e-9f50-408b-9e70-e84cecf3fd6e&type=display
unhealthy
Health Status: unhealthy
Condition: Paroxysmal supraventricular tachycardias|paroxysmal atrial fibrillation/flutter|Sustained ventricular tachycardia
Sources:
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fa68b35e-9f50-408b-9e70-e84cecf3fd6e&type=display
Ventricular tachycardia Disc. AE
200 mg 2 times / day multiple, oral
Recommended
Dose: 200 mg, 2 times / day
Route: oral
Route: multiple
Dose: 200 mg, 2 times / day
Sources:
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fa68b35e-9f50-408b-9e70-e84cecf3fd6e&type=display
unhealthy
Health Status: unhealthy
Condition: Paroxysmal supraventricular tachycardias|paroxysmal atrial fibrillation/flutter|Sustained ventricular tachycardia
Sources:
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fa68b35e-9f50-408b-9e70-e84cecf3fd6e&type=display
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inhibitor
1767
substrate
1217

inhibitor
1852
inhibitor
1612

OverviewOther

Other InhibitorOther SubstrateOther Inducer
OCT2
647
CYP1A2
1054
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP2D6
1891
 yes [IC50 0.44 uM]
CYP2C9
1819
 yes [IC50 0.49 uM]
OCT2
648
 yes [IC50 191 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP1A2
1054
 yes
CYP2D6
1217
 yes
yes (co-administration study)
Comment: During the period in which the CYP2D6 inhibitor paroxetine was administered, the flecainide AUC in extensive and intermediate metabolizers was increased to 128.5% of basal values (90% CI, 122.2%– 135.2%) and 116.6% of basal values (90% CI, 107.3%–126.8%). However, poor metabolizers exhibited no alterations in AUC after administration of paroxetine (pharmacogenomic studies were also performed)
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
1647
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:75984
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:75984
ChemicalBook
CB0663265
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB0663265
MolPort
MolPort-003-847-380
https://www.molport.com/shop/molecule-link/MolPort-003-847-380
eMolecules
901891
https://www.emolecules.com/cgi-bin/more?vid=901891
PubMed

PubMed

TitleDatePubMed
Comparative haemodynamic effects of intravenous lignocaine, disopyramide and flecainide in uncomplicated acute myocardial infarction.
1986 Dec
Dysarthria and visual hallucinations due to flecainide toxicity.
1986 Jan
Flecainide acetate in the treatment of tachycardias associated with Mahaim fibres.
1987 Aug
[Drug-induced intrahepatic cholestasis caused by flecainide acetate and enalapril].
1987 Mar
Flecainide-induced sustained ventricular tachycardia successfully treated with lidocaine.
1987 Sep
Rapid suppression of flecainide-induced incessant ventricular tachycardia with high-dose intravenous amiodarone.
1988 Apr
[Central nervous system side effects due to anti-arrhythmia therapy. Psychotic depression due to flecainide].
1988 Mar 11
Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. A multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Flecainide Supraventricular Tachycardia Study Group.
1989 Dec
Cardioprotective effects of various class I antiarrhythmic drugs in canine hearts.
1989 Jul
[Bidirectional tachycardia during therapy with lorajmine].
1989 Oct
Generalized seizures as the presentation of flecainide toxicity.
1989 Oct
Acute urinary retention associated with flecainide.
1990 Jan-Feb
Serious interactions of sotalol with amiodarone and flecainide.
1990 Mar 5
Amiodarone toxicity: myopathy and neuropathy.
1990 May
[Effects of oral flecainide treatment of refractory tachyarrhythmias].
1990 May
Combined application of class I antiarrhythmic drugs causes "additive", "reductive", or "synergistic" sodium channel block in cardiac muscles.
1990 Nov
Relative efficacy and safety of intravenous drugs for termination of sustained ventricular tachycardia.
1990 Sep 15
Proarrhythmia, cardiac arrest and death in young patients receiving encainide and flecainide. The Pediatric Electrophysiology Group.
1991 Aug
Flecainide acetate treatment of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation: dose-response studies. The Flecainide Supraventricular Tachycardia Study Group.
1991 Feb
Safety and efficacy of oral flecainide therapy in patients with atrioventricular re-entrant tachycardia.
1991 Feb 1
Flecainide acetate prevents recurrence of symptomatic paroxysmal supraventricular tachycardia. The Flecainide Supraventricular Tachycardia Study Group.
1991 Jan
Reversion of recent-onset atrial fibrillation to sinus rhythm by intravenous flecainide.
1991 Jan 15
Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.
1991 Mar 21
Flecainide in quinidine-resistant atrial fibrillation.
1992 Aug 20
Effects of advancing age on the efficacy and side effects of antiarrhythmic drugs in post-myocardial infarction patients with ventricular arrhythmias. The CAST Investigators.
1992 Jul
Use of ibutilide in cardioversion of patients with atrial fibrillation or atrial flutter treated with class IC agents.
2004 Aug 18
Electrocardiographical case. Asymptomatic patient with ST-segment elevation.
2004 Nov
A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system.
2005 Feb
Long-term results of hybrid therapy in patients with atrial fibrillation who develop atrial flutter during flecainide infusion.
2005 Jan
Assessment of serum flecainide trough levels in patients with tachyarrhythmia.
2005 Jan
Flecainide-induced neuropathy.
2005 Sep
Long-term protection of central axons with phenytoin in monophasic and chronic-relapsing EAE.
2006 Dec
Management of atrial fibrillation.
2007
Further evidence of inherited long QT syndrome gene mutations in antiarrhythmic drug-associated torsades de pointes.
2007 May
Flecainide cardiotoxicity precipitated by electrolyte imbalance. Caution with thiazide diuretics.
2007 May
The Relationship Between HIV Infection and Cardiovascular Disease.
2008 Aug
Drug therapy considerations in arrhythmias in children.
2008 Aug 1
Ventricular dysfunction: tachycardia induced cardiomyopathy.
2008 May 1
ECGs in the ED.
2008 Nov
Role of cytochrome P450 in drug interactions.
2008 Oct 18
A preliminary assessment of the effects of ATI-2042 in subjects with paroxysmal atrial fibrillation using implanted pacemaker methodology.
2009 Apr
Is flecainide dangerous in long QT-3 patients?
2009 Jan
Delirium in a patient with toxic flecainide plasma concentrations: the role of a pharmacokinetic drug interaction with paroxetine.
2009 Jul
Effects of antiarrhythmic drugs on the hyperpolarization-activated cyclic nucleotide-gated channel current.
2009 Jun
A case of flecainide-induced hyponatremia.
2009 Oct
Tpeak-Tend interval and Tpeak-Tend/QT ratio as markers of ventricular tachycardia inducibility in subjects with Brugada ECG phenotype.
2010 Feb
Tachycardia due to atrial flutter with rapid 1:1 conduction following treatment of atrial fibrillation with flecainide.
2010 Mar 10
Selective regulation of cardiac organic cation transporter novel type 2 (OCTN2) in dilated cardiomyopathy.
2011 Jun
Comparison of a genomic and a multiplex cell imaging approach for the detection of phospholipidosis.
2011 Oct
Estimating the risk of drug-induced proarrhythmia using human induced pluripotent stem cell-derived cardiomyocytes.
2011 Sep
Patents

Patents

076278-001
2
US20100184990
2
US4938966
2

Sample Use Guides

In Vivo Use Guide
Usual Adult Dose for Ventricular Tachycardia Initial dose: 100 mg orally every 12 hours. Maintenance dose: May be increased in increments of 50 mg bid every 4 days until efficacy is achieved. Most patients with SUSTAINED VT do not require more than 150 mg every 12 hours (300 mg/day), and the maximum dose recommended is 400 mg/day. Usual Adult Dose for Atrial Fibrillation Initial dose: 50 mg orally every 12 hours. Maintenance dose: May be increased in increments of 50 mg bid every 4 days until efficacy is achieved.
Route of Administration: Oral
In Vitro Use Guide
Flecainide produced a dose-dependent prolongation of the cardiac action potential at 1 and 3uM in human pluripotent stem cell-derived cardiomyocytes.
Substance Class Chemical
Created
by admin
on Sat Dec 16 17:45:40 GMT 2023
Edited
by admin
on Sat Dec 16 17:45:40 GMT 2023
Record UNII
K94FTS1806
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
FLECAINIDE
INN   MI   VANDF   WHO-DD  
INN  
Official Name English
N-(2-PIPERIDYLMETHYL)-2,5-BIS(2,2,2-TRIFLUOROETHOXY)BENZAMIDE
Systematic Name English
FLECAINIDE [VANDF]
Common Name English
THN102 COMPONENT FLECAINIDE
Common Name English
THN-102 COMPONENT FLECAINIDE
Code English
Flecainide [WHO-DD]
Common Name English
FLECAINIDE [MI]
Common Name English
NSC-719273
Code English
flecainide [INN]
Common Name English
Classification Tree Code System Code
NDF-RT N0000175426
Created by admin on Sat Dec 16 17:45:41 GMT 2023 , Edited by admin on Sat Dec 16 17:45:41 GMT 2023
WHO-VATC QC01BC04
Created by admin on Sat Dec 16 17:45:41 GMT 2023 , Edited by admin on Sat Dec 16 17:45:41 GMT 2023
LIVERTOX NBK548023
Created by admin on Sat Dec 16 17:45:41 GMT 2023 , Edited by admin on Sat Dec 16 17:45:41 GMT 2023
FDA ORPHAN DRUG 536716
Created by admin on Sat Dec 16 17:45:41 GMT 2023 , Edited by admin on Sat Dec 16 17:45:41 GMT 2023
WHO-ATC C01BC04
Created by admin on Sat Dec 16 17:45:41 GMT 2023 , Edited by admin on Sat Dec 16 17:45:41 GMT 2023
NCI_THESAURUS C47793
Created by admin on Sat Dec 16 17:45:41 GMT 2023 , Edited by admin on Sat Dec 16 17:45:41 GMT 2023
NCI_THESAURUS C93038
Created by admin on Sat Dec 16 17:45:41 GMT 2023 , Edited by admin on Sat Dec 16 17:45:41 GMT 2023
Code System Code Type Description
MERCK INDEX
m5400
Created by admin on Sat Dec 16 17:45:41 GMT 2023 , Edited by admin on Sat Dec 16 17:45:41 GMT 2023
PRIMARY Merck Index
PUBCHEM
3356
Created by admin on Sat Dec 16 17:45:41 GMT 2023 , Edited by admin on Sat Dec 16 17:45:41 GMT 2023
PRIMARY
NCI_THESAURUS
C62029
Created by admin on Sat Dec 16 17:45:41 GMT 2023 , Edited by admin on Sat Dec 16 17:45:41 GMT 2023
PRIMARY
EVMPD
SUB07637MIG
Created by admin on Sat Dec 16 17:45:41 GMT 2023 , Edited by admin on Sat Dec 16 17:45:41 GMT 2023
PRIMARY
MESH
D005424
Created by admin on Sat Dec 16 17:45:41 GMT 2023 , Edited by admin on Sat Dec 16 17:45:41 GMT 2023
PRIMARY
DAILYMED
K94FTS1806
Created by admin on Sat Dec 16 17:45:41 GMT 2023 , Edited by admin on Sat Dec 16 17:45:41 GMT 2023
PRIMARY
NSC
719273
Created by admin on Sat Dec 16 17:45:41 GMT 2023 , Edited by admin on Sat Dec 16 17:45:41 GMT 2023
PRIMARY
RXCUI
4441
Created by admin on Sat Dec 16 17:45:41 GMT 2023 , Edited by admin on Sat Dec 16 17:45:41 GMT 2023
PRIMARY RxNorm
CHEBI
75984
Created by admin on Sat Dec 16 17:45:41 GMT 2023 , Edited by admin on Sat Dec 16 17:45:41 GMT 2023
PRIMARY
FDA UNII
K94FTS1806
Created by admin on Sat Dec 16 17:45:41 GMT 2023 , Edited by admin on Sat Dec 16 17:45:41 GMT 2023
PRIMARY
DRUG CENTRAL
1176
Created by admin on Sat Dec 16 17:45:41 GMT 2023 , Edited by admin on Sat Dec 16 17:45:41 GMT 2023
PRIMARY
WIKIPEDIA
FLECAINIDE
Created by admin on Sat Dec 16 17:45:41 GMT 2023 , Edited by admin on Sat Dec 16 17:45:41 GMT 2023
PRIMARY
DRUG BANK
DB01195
Created by admin on Sat Dec 16 17:45:41 GMT 2023 , Edited by admin on Sat Dec 16 17:45:41 GMT 2023
PRIMARY
CAS
54143-55-4
Created by admin on Sat Dec 16 17:45:41 GMT 2023 , Edited by admin on Sat Dec 16 17:45:41 GMT 2023
PRIMARY
EPA CompTox
DTXSID8023054
Created by admin on Sat Dec 16 17:45:41 GMT 2023 , Edited by admin on Sat Dec 16 17:45:41 GMT 2023
PRIMARY
LACTMED
Flecainide
Created by admin on Sat Dec 16 17:45:41 GMT 2023 , Edited by admin on Sat Dec 16 17:45:41 GMT 2023
PRIMARY
SMS_ID
100000080972
Created by admin on Sat Dec 16 17:45:41 GMT 2023 , Edited by admin on Sat Dec 16 17:45:41 GMT 2023
PRIMARY
ChEMBL
CHEMBL652
Created by admin on Sat Dec 16 17:45:41 GMT 2023 , Edited by admin on Sat Dec 16 17:45:41 GMT 2023
PRIMARY
IUPHAR
2560
Created by admin on Sat Dec 16 17:45:41 GMT 2023 , Edited by admin on Sat Dec 16 17:45:41 GMT 2023
PRIMARY
INN
4096
Created by admin on Sat Dec 16 17:45:41 GMT 2023 , Edited by admin on Sat Dec 16 17:45:41 GMT 2023
PRIMARY
Related Record Type Details
Structure of FLECAINIDE ACETATE
SALT/SOLVATE -> PARENT
SODIUM CHANNEL PROTEIN TYPE 5 SUBUNIT ALPHA
TARGET -> INHIBITOR
OCT-2
TRANSPORTER -> INHIBITOR
Related Record Type Details
Structure of FLECAINIDE META-O-DEALKYLATED
METABOLITE -> PARENT
Structure of 5-HYDROXY-N-((6-OXO-2-PIPERIDINYL)METHYL)-2-(2,2,2-TRIFLUOROETHOXY)BENZAMIDE
METABOLITE -> PARENT
Related Record Type Details
Structure of FLECAINIDE
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966